von Minckwitz, Gunter <br/><br/>
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.  [electronic resource] 

 -  The Lancet. Oncology  Oct 2014 
 - 1269-78 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(14)70439-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Bevacizumab<br/>Breast Neoplasms--drug therapy<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Follow-Up Studies<br/>Genes, erbB-2--genetics<br/>Humans<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasm Invasiveness--pathology<br/>Neoplasm Recurrence, Local--drug therapy<br/>Neoplasm Staging<br/>Patient Selection<br/>Remission Induction--methods<br/>Retreatment<br/>Survival Analysis<br/>Time Factors<br/>Treatment Outcome